A mother's age at menopause may predict her daughter's fertility in terms of the numbers of eggs remaining in her ovaries, according to the new research published online in Europe's leading reproductive medicine journal Human Reproduction  today.
By assessing ovarian reserve with two accepted methods – levels of anti-Müllerian hormone (AMH) and antral follicle count (AFC) – in daughters and comparing it with the age of menopause in their mothers, researchers found that both AMH and AFC declined faster in women whose mothers had an early menopause compared to women whose mothers had a late menopause. The number of eggs remaining in a woman's ovary is related to a reduction in her ability to conceive naturally, with both the number and quality of eggs starting to decline as she gets older.
Dr. Janne Bentzen from the Copenhagen University Hospital, Rigshospitalet, in Copenhagen, Denmark, who led the research, said: "This is the first study to suggest that the age-related decline of AMH and AFC may differ between those whose mothers entered menopause before the age of 45 years and those whose mothers entered menopause after the age of 55 years. Our findings support the idea that the ovarian reserve is influenced by hereditary factors. However, long-term follow-up studies are required. Conclusive evidence can only be obtained when we have longitudinal studies that follow women who have AMH measurements over time until menopause. Therefore, interpretations of our data are limited and the findings we have described may not occur in any given individual."
Previous research has suggested that there is about 20 years between a woman's fertility starting to decline and the onset of menopause. So a woman who enters the menopause at 45 may have experienced a decline in her fertility at the age of 25. Dr Bentzen said: "Epidemiological studies have established a link between the age at menopause among mothers and daughters. In line with the suggested 20-year interval between the first decline in fertility and the menopause, we hypothesised that maternal factors may also have an impact on a woman's fertility potential in terms of ovarian reserve."
The researchers recruited 527 women working in health care at the Copenhagen University Hospital, who were aged between 20-40 years and whose mothers' age at natural menopause was known. They divided them into three categories: those whose mothers had an early menopause (younger than 45); normal maternal age at menopause (46-54 years); and late maternal age at menopause (older than 55).
They used transvaginal sonography to count the number of antral follicles in the women's ovaries. Follicles are clusters of cells that contain the immature egg. Every woman is born with about two million of them, but only 400 will ever mature enough to release an egg for fertilisation during a woman's reproductive lifespan. Levels of AMH were measured from blood samples. The researchers also took a medical history, including details of smoking habits in mothers and daughters, oral contraceptive use and body mass index (BMI).
After adjusting for various factors that could affect the results (e.g. smoking, contraceptive use, age and BMI), they found that average AMH levels declined by 8.6%, 6.8% and 4.2% a year in the groups of women with mothers who had early, normal or late menopauses respectively. A similar pattern was seen for AFC, with annual declines of 5.8%, 4.7% and 3.2% in the same groups respectively.
The study also found that AMH levels and AFC were significantly lower (27.3% and 26.8% lower respectively) in oral contraceptive users compared with non-users. AFC in women whose mothers smoked while they were pregnant was an average of 11% lower, but there was no significant effect on AMH levels.
Dr. Bentzen said the effect of oral contraceptive use was likely to be temporary and unlikely to influence the long-term decline in ovarian follicles. However, she said clinicians and women should be aware of it when considering women's reproductive life spans or any fertility treatments. "We believe there is a need for longitudinal, large studies in which ovarian reserve parameters are measured repeatedly in the same individual before, during and after the use of oral contraceptives. Additionally, we need to explore the impact of dose-response and duration of hormonal contraception on markers of ovarian reserve," she said.
In their paper, the authors write: "Clearly, our data do not elucidate whether maternal age at menopause is a direct predictor of age at menopause of the offspring, or the chance of pregnancy. Nevertheless, from a biological point of view, it may be reasonable to assume that a low ovarian reserve may have a long-term effect that will shorten the reproductive lifespan. We therefore assume that markers such as 'maternal age at menopause' in combination with AMH or AFC, and chronological age may represent a more complete picture when evaluating the ovarian reserve of the individual. This assumption awaits longitudinal studies before it can be put to test."
 "Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age", by J.G. Bentzen, J.L. Forman, E.C. Larsen, A. Pinborg, T.H. Johannsen, L. Shmidt, L. Friis-Hansen, and A. Nyboe Andersen. Human Reproduction. doi:10.1093/humrep/des356
European Society of Human Reproduction and Embryology: http://www.eshre.com
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?
It is only in the aftermath of treatment that survivors discern that their adrenalin alone wont fuel the rest of their recovery. For many, surviving cancer is followed by even more hardship
Just down the road from Facebook and Google, Dr. Phil Wagner runs a laboratory dedicated to optimizing the performance of some of the world's top athletes. At Sparta Performance Science in Menlo Park, California, Wagner and his team bring the spirit of Silicon Valley to bear on the athletic world, helping athletes find the tiny advantages that add to championships. Join us for a trip inside the lab to see where sports meets science.
Pieter Cohen, an internist in Massachusetts, got interested in dietary supplements several years ago, when some of his …
The risk of overdiagnosis and false positives means the UK may be barking up the wrong tree in trialling a wider target age range for breast screening